

# Antibe Therapeutics Inc

08:55 04 May 2020

## Antibe Therapeutics expects results from Phase 2B study of pain drug ATB-346 within six weeks

Antibe Therapeutics Inc (CVE:ATE) (OTCQB:ATBPF) has told shareholders that it expects to release topline results from the Phase 2B study of its flagship pain drug ATB-346 within six weeks.

The company said that its clinical research organization Veristat completed the trial and was able to capture all patient data from 360 participants across 40 clinical sites.

Toronto-based Antibe's original timeline to release results was impacted by the ongoing coronavirus (COVID-19) pandemic that caused governments and healthcare providers to impose hospital restrictions and clinic closures.

### READ: Echelon rates Antibe Therapeutics as 'top pick' as investors eagerly await Phase II data from ATB-346 study

The restrictions, coupled with work-from-home constraints, slowed Veristat's data collection, validation and analysis beyond the original timeframe, Antibe told shareholders.

"Although the world is facing singular challenges in light of the COVID-19 health crisis, we are fortunate to have successfully completed the collection of data for every patient enrolled in the study," Antibe CEO Dan Legault said in a statement.

"Validating and processing these data is a non-trivial task in the current environment, especially given the study's large number of sites. Although later than anticipated, we look forward to delivering robust and complete top-line data as soon as possible."


ATB-346 is being developed to work as an alternative to nonsteroidal anti-inflammatory drugs, or NSAIDs. The current Phase 2 trial is designed to validate ATB-346's effectiveness compared to placebo in reducing osteoarthritis pain.

Antibe also said its cash balance of C\$6 million was sufficient to see the company through the upcoming data readout and beyond.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

### 1 Year Share Price Graph



November 2019 May 2020 November 20

### Share Information

**Code:** ATE  
**Listing:** TSX-V  
**Sector:** Pharma & Biotech  
**Website:** [antibetherapeutics.com](http://antibetherapeutics.com)

### Company Synopsis:

*Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a \$20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).